Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

New Delhi: Torrent Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabetes ... subcutaneous semaglutide 7.2 mg compared with Wegovy and placebo ...

25 mg oral formulation of Wegovy ® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major ...

NCT05564117), a 64-week study that included a 12-week dose escalation and a 7-week off-treatment follow-up period. Study participants were randomly assigned 2:1 to receive oral semaglutide 25 mg ...